Résultats de la recherche

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic...

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...